Dermatomyositis – Medxy AI

Skin-Specific Outcomes of Brepocitinib in Dermatomyositis: Evidence from a Phase 3 Randomized Clinical Trial and Secondary Analysis

By MedXY 09/03/2026

Brepocitinib, a selective TYK2-JAK1 inhibitor, showed rapid, sustained skin disease control, itch relief, and improved quality of life in dermatomyositis patients over 52 weeks with an acceptable safety profile in a global phase 3 trial.

Dermatology news Respiratory

Serum Amyloid A as a Prognostic Biomarker in Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease

By MedXY 09/03/2026

Elevated serum amyloid A correlates with rapidly progressive interstitial lung disease and mortality in dermatomyositis, with combined assessment alongside anti-MDA5 antibody improving risk stratification.

Dermatology news Rheumatology

The TIP-CA Model: A Validated Tool to Stratify Cancer Risk in Adult Dermatomyositis Patients

By MedXY 03/04/2026

Researchers have developed and validated the TIP-CA model, a clinical tool using five key factors—anti-TIF1-γ, ILD absence, poikiloderma, DM subtype, and anemia—to accurately predict malignancy risk in patients with dermatomyositis, enabling earlier detection and personalized screening.